The FDA on October 2, 2025, approved ZEPZELCA® in combination with Atezolizumab (TECENTRIQ®) or Atezolizumab and Hyaluronidase-tqjs (TECENTRIQ HYBREZA®) for the maintenance treatment of adult patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with TECENTRIQ® or TECENTRIQ HYBREZA®, Carboplatin, and Etoposide. ZEPZELCA® is a product of Jazz Pharmaceuticals, Inc. and TECENTRIQ® as well as TECENTRIQ HYBREZA® are products of Genentech Inc.
Bottom Ad
Advertisement
Subscribe
